Option chain shows key data for Quizam Media's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Quizam Media.

Quizam Media (OTC:QQQFF) Stock, Option Chain

Quizam Media Corp is a company whose principal business activities consist of providing computer training and consulting services, marketing of a computer-based educational program, film production and cannabis retail sales. The Company derives revenue from two industries, Software and Cannabis. Software includes revenue from training services, software sales and licensing sales. Cannabis includes retail product sales and consulting fee revenue. The company does its sales via geographical segments that include Canada, USA and Europe. The majority of its revenue is derived from Canada.

Cannabis

Government

Penny Stocks

Small Cap

Markets

General

AFCG

GRWG

HYFM

IIPR

LFLY

NLCP

QUIZAM MEDIA CORP ORD by Quizam Media Corporation

QQQFF

REFI

SSIC

UGRO

The graph depicts the stock price performance of baskets of stocks in six different cannabis industry subsectors. Each basket consists of the top four or five U.S. companies in each group. The stocks in each basket are equally weighted, and the basket prices are indexed so that August 25, 2023 (the Friday before the HHS announcement) equals 100.

Cannabis Chart Of The Week: Are Ancillary Sectors Participating In The Rescheduling Price Upswing?

Quizam to produce new Climate Change Documentary Film entitled &#34;Forest for the Fires&#34;

Quizam Increases Private Placement to $240,000

QUIZAM MEDIA CORP by Quizam Media Corporation

Quizam Media Corp

Chardan Capital analyst Daniil Gataulin maintains Cognition Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGTX#NASDAQ">CGTX</a>) with a Buy and maintains $11 price target.

News

Price Target

Analyst Ratings

CGTX

Chardan Capital Maintains Buy on Cognition Therapeutics, Maintains $11 Price Target

Biotech

Health Care

PHIO

Phio Pharmaceuticals Announced That The Safety Monitoring Committee Recommended Dose Escalation In Its Phase 1B Trial To Evaluate The Safety And Tolerability Of PH-762 For Stages 1, 2, And 4 Cutaneous Squamous Cell Carcinoma, Stage 4 Melanoma, And Stage 4 Merkel Cell Carcinoma

"We are encouraged by the early evidence of responses in patients with cold tumors, including MSS colorectal cancer, reported for the combination of vilastobart and atezolizumab in Phase 1C dose escalation earlier this year, and we look forward to sharing initial Phase 2 data for the combination in MSS CRC at ASCO GI in January," said Katarina Luptakova, M.D., chief medical officer of Xilio.
"In addition, the preliminary Phase 1 data we reported today for XTX301, our tumor-activated IL-12, highlight its promising clinical profile, including no dose-limiting toxicities reported to date and consistent interferon gamma signaling observed throughout treatment cycles."

Xilio To Present Initial Data From Its Ongoing Phase 2 Trial For Vilastobart At ASCO GI; Reports Preliminary Phase 1 Data For XTX301 Showing Improved Tolerability Profile Over Historical Data For rhIL-12

Deutsche Bank analyst David Begleiter maintains PPG Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PPG#NYSE">PPG</a>) with a Buy and lowers the price target from $150 to $145.

Deutsche Bank Maintains Buy on PPG Indus, Lowers Price Target to $145

The most oversold stocks in the industrials sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the<a href="https://www.benzinga.com/topic/rsi"> RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Paychex Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAYX#NASDAQ">PAYX</a>)</h3>
<ul>
<li>On Nov. 19, JP Morgan analyst Tien-Tsin Huang maintained Paychex with an Underweight rating and raised the price target from $133 to $139. The company's stock fell around 4% over the past five days and has a <a href="https://www.benzinga.com/quote/PAYX">52-week low of $114.72</a>.</li>
<li>RSI Value: 29.58&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>PAYX Price Action: Shares of Paychex fell 3.2% to close at $135.86 on Wednesday.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent121924&amp;t=be2bearmibe3na1">latest PAYX news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent121924&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="908" height="850" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/19074317/image-164.png" alt="" class="wp-image-699579" style="width:617px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/19074317/image-164.png 908w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/19074317/image-164-300x281.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/19074317/image-164-768x719.png 768w" sizes="(max-width: 908px) 100vw, 908px" /></a></figure>
<h3 class="wp-block-heading">Sunrun Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</h3>
<ul>
<li>On Dec. 17, Goldman Sachs analyst Brian Lee maintained Sunrun with a Buy and lowered the price target from $19 to $17. The company's stock fell around 12% over the past five days and <a href="https://www.benzinga.com/quote/RUN">has a 52-week low</a> of $9.13.</li>
<li>RSI Value: 28.40</li>
<li>RUN Price Action: Shares of Sunrun fell 9.1% to close at $9.15 on Wednesday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent121924&amp;t=be2bearmibe3na1"> trend in RUN stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent121924&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="916" height="842" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/19074410/image-165.png" alt="" class="wp-image-699581" style="width:630px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/19074410/image-165.png 916w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/19074410/image-165-300x276.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/19074410/image-165-768x706.png 768w" sizes="(max-width: 916px) 100vw, 916px" /></a></figure>
<h3 class="wp-block-heading">A O Smith Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AOS#NYSE">AOS</a>)</h3>
<ul>
<li>On Dec. 11, Stifel analyst Nathan Jones maintained A.O. Smith with a Buy and lowered the price target from $91 to $90. The company's stock fell around 5% over the past five days and has a 52-week <a href="https://www.benzinga.com/quote/AOS">low of $68.89.</a></li>
<li>RSI Value: 25.09</li>
<li>AOS Price Action: Shares of A O Smith fell 2.7% to close at $68.91 on Wednesday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent121924&amp;t=be2bearmibe3na1">breakout in AOS shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent121924&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="927" height="836" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/19074507/image-166.png" alt="" class="wp-image-699582" style="width:567px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/19074507/image-166.png 927w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/19074507/image-166-300x271.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/19074507/image-166-768x693.png 768w" sizes="(max-width: 927px) 100vw, 927px" /></a></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42553288/top-3-tech-and-telecom-stocks-that-may-crash-this-month">Top 3 Tech And Telecom Stocks That May Crash This Month</a></li>
</ul>

Long Ideas

Pre-Market Outlook

Trading Ideas

PAYX

Top 3 Industrials Stocks Which Could Rescue Your Portfolio For December

Deutsche Bank analyst David Begleiter maintains Axalta Coating Sys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXTA#NYSE">AXTA</a>) with a Buy and lowers the price target from $44 to $42.

AXTA

Deutsche Bank Maintains Buy on Axalta Coating Sys, Lowers Price Target to $42

Wells Fargo analyst Derek Archila downgrades Cabaletta Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CABA#NASDAQ">CABA</a>) from Overweight to Equal-Weight and lowers the price target from $12 to $6.

Downgrades

CABA

Wells Fargo Downgrades Cabaletta Bio to Equal-Weight, Lowers Price Target to $6

Keybanc analyst Eric Heath upgrades Fortinet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTNT#NASDAQ">FTNT</a>) from Sector Weight to Overweight and announces $115 price target.

Upgrades

FTNT

Keybanc Upgrades Fortinet to Overweight, Announces $115 Price Target

Deutsche Bank analyst Steve Powers maintains General Mills (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GIS#NYSE">GIS</a>) with a Hold and lowers the price target from $72 to $68.

Deutsche Bank Maintains Hold on General Mills, Lowers Price Target to $68

Deutsche Bank analyst Krisztina Katai maintains Birkenstock Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIRK#NYSE">BIRK</a>) with a Buy and raises the price target from $65 to $66.

BIRK

Deutsche Bank Maintains Buy on Birkenstock Holding, Raises Price Target to $66

Wells Fargo analyst Derek Archila upgrades C4 Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCCC#NASDAQ">CCCC</a>) from Equal-Weight to Overweight and raises the price target from $8 to $12.

CCCC

Wells Fargo Upgrades C4 Therapeutics to Overweight, Raises Price Target to $12

NLSP

NLS Pharmaceutics And Kadimastem In Collaboration With iTolerance Announced That Request For Pre-Investigational New Drug Meeting Has Been Submitted To The FDA For iTOL102 For Type 1 Diabetes

The Company's net income for 1H 2024 was $44,000 as compared to net loss of $255,000 for 1H 2023 resulting from increase in gross profit.

CLWT

Euro Tech Holdings H1 2024 Revenue $7.259M, Down From $7.957M YoY

Keybanc analyst Eric Heath upgrades Okta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKTA#NASDAQ">OKTA</a>) from Sector Weight to Overweight and announces $115 price target.

OKTA

Keybanc Upgrades Okta to Overweight, Announces $115 Price Target

Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) is reportedly in early discussions with officials of the city of Austin, Texas, to roll out its <a href="https://www.benzinga.com/topic/tesla-cybercab">autonomous vehicles for testing</a> as early as 2025.
What Happened: Elon Musk-led Tesla's driverless vehicle ambitions could get a boost if its discussions with Austin City bear fruit.
According to a <a href="https://www.bloomberg.com/news/articles/2024-12-19/tesla-sounds-out-austin-officials-about-long-promised-driverless-fleets">report</a> by Bloomberg, a Tesla employee has been in touch with Austin city officials since as early as May to create a safety framework for deploying driverless fleets.
Reacting to the news, the Tesla stock surged over 3% in premarket trading to hover at $453.91, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro data</a>.
See Also: <a href="https://www.benzinga.com/tech/24/12/42570564/tesla-says-powerwall-owners-generated-4-5-twh-of-solar-energy-this-year-amid-energy-segment-revenue-boom">Tesla Says Powerwall Owners Generated 4.5 TWh Of Solar Energy This Year Amid Energy Segment Revenue Boom</a>
Why It Matters: Tesla's autonomous driving ambitions have been a key area of focus as analysts determine the impact of a driverless fleet on the EV giant's prospects.
Wedbush analyst Dan Ives and long-time Tesla bull thinks the Tesla stock could hit the <a href="https://www.benzinga.com/24/12/42455654/wedbush-securities-sees-tesla-touching-2-trillion-market-cap-by-2025-end-apple-microsoft-nvidia-to-join-4-trillion-market-cap-club-next-year-says-analyst">$2 trillion market capitalization mark</a> by the end of 2025, in a bull-case scenario.
"We believe with the autonomous story at Tesla worth $1 trillion alone that in a bull case scenario by the end of 2025, Tesla could achieve a $2 trillion market cap threshold," Ives said. "FSD, autonomous, and the launch of Cybercab for early 2026 are keys for Tesla.&#8221;
Tesla has also been <a href="https://www.benzinga.com/tech/24/11/42230503/tesla-cybercab-spotted-testing-in-giga-texas-facility">spotted testing the Cybercab</a> at the Giga Texas facility. A video shared on social media showcased the Cybercab navigating traffic autonomously within the premises.
Price Action: On a year-to-date basis, the stock is up 77.2%. <a href="https://www.benzinga.com/quote/TSLA/analyst-ratings">Here&#8217;s what other analysts are saying.</a>
Check out more of Benzinga's Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42571913/tesla-registrations-drop-by-nearly-41-in-november-in-eu-dragging-down-optimism-for-over-500000-ev-deliveries-in-q4">Tesla EU Registrations Plunge 41% In November, Casting Shadow On Q4 Target Of Over 500,000 EV Deliveries</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Image via Tesla

Equities

Tech

TSLA

Tesla Reportedly In Talks With Austin To Bring Autonomous Vehicles To Texas Roads: Elon Musk-Led EV Giant Rises 3% In Pre Market

Wells Fargo analyst Steven Cahall upgrades Tegna (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGNA#NYSE">TGNA</a>) from Equal-Weight to Overweight and announces $23 price target.

TGNA

Wells Fargo Upgrades Tegna to Overweight, Announces $23 Price Target

Wells Fargo initiates coverage on Pennant Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PNTG#NASDAQ">PNTG</a>) with a Equal-Weight rating and announces Price Target of $33.

Initiation

PNTG

Wells Fargo Initiates Coverage On Pennant Gr with Equal-Weight Rating, Announces Price Target of $33

Wells Fargo analyst Derek Archila downgrades Monte Rosa Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLUE#NASDAQ">GLUE</a>) from Overweight to Equal-Weight and lowers the price target from $14 to $11.

GLUE

Wells Fargo Downgrades Monte Rosa Therapeutics to Equal-Weight, Lowers Price Target to $11

Conagra Brands Lowers FY25 Outlook: Sees Adjusted EPS Between $2.45-$2.50 Vs. $2.58 Estimate (Prior View: $2.60-$2.65), Projects Organic Net Sales Near The Midpoint Of (1.5)% To Flat YoY

The new facility will accommodate drone manufacturing and assembly, R&amp;D, sales, pilot, and training teams, and has an aeronautical test range site for demonstrations.

ZENA

ZenaTech Subsidiary Moves Into Its Manufacturing Facility In Phoenix, Arizona To Produce US Defense And Nato Drones, Part Of Efforts To Produce 'Made In America' Drones

Comments

Quizam Media

Quizam Media (QQQFF) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga